Company Interview / Emyria pioneering PTSD treatment

Greg Hutchinson of Emyria (ASX: EMD) highlights the promising results of their PTSD programme using MDMA. He mentions that TGA-approved therapy involving ecstasy aids in addressing PTSD, showing significant improvement in patients who had little benefit from conventional treatments.

Greg shares that Emyria's (ASX: EMD) trials include therapy as an integral part of the treatment, and plans are in place to expand and involve insurers to make treatment more accessible. The addressable market for PTSD and treatment-resistant depression utilising psilocybin amounts to over $30 billion.

Emyria (ASX: EMD) aims to open clinics nationwide, requiring significant capital for expansion. Greg points out the substantial barriers to entry, including securing authorised prescriber status and pharmaceutical-grade medication. However, the company is confident in their ability to grow and meet demand.